Arbutus Biopharma Corp
ABUS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$807.66M
Close$
$-2.83
169.3% downside
Current Fair Value
169.3% downsideOvervalued by 169.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $807.66 Million |
|---|---|
| Enterprise Value | $543.79 Million |
| Earnings per Share | $-0.17 |
| Beta | 0.62 |
| Outstanding Shares | 197,470,724 |
Return
| Return on Equity | 256.47% |
|---|---|
| Return on Assets | 64.74% |
| Return on Invested Capital | 220.40% |
Valuation & Multiples
| P/E Ratio | 4.62 |
|---|---|
| PEG | -0.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3 |
| Enterprise Value to EBIT | 2.52 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 11, 2026
EPS Estimate
-$0.02
Consensus analyst estimateRevenue Estimate
$1.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
-$0.02
Consensus analyst estimateRevenue Estimate
$1.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.26, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.2600▼ 69.02% |
|---|---|
| Total Calls | 250,000▲ 33.98% |
| Total Puts | 65,000▼ 63.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.05%▼ 66.88% |
|---|---|
| Total Invested | $47.70M▼ 93.00% |
| Investors Holding | 51▼ 131.00% |
About Arbutus Biopharma Corp
CEO: William Collier
